Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Drug Clearance: Overview

Drug Clearance: Overview

Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PTEN acts as a master mediator of nonhealing venous leg ulcers by suppressing immune response, angiogenesis, and lymphangiogenesis.

Science translational medicine·2026

Same author

Bone health in women with hidradenitis suppurativa: addressing osteoporosis risks and management options.

International journal of women's dermatology·2026

Same author

Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II.

Dermatology and therapy·2026

Same author

A bioelectric dressing improves postderoofing outcomes in hidradenitis suppurativa by microbiome modulation: A split-body, randomized clinical trial.

JID innovations : skin science from molecules to population health·2026

Same author

Symposium on Hidradenitis Suppurativa Advances 2025 Proceedings.

Dermatology and therapy·2026

Same author

Ethical considerations in managing hidradenitis suppurativa in women of childbearing potential.

Journal of the American Academy of Dermatology·2026

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Published on: November 8, 2024

Alefacept - a drug review.

Hadar Lev-Tov¹, Suhail Hadi

¹Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th, Street, Box 1048, 5th Floor, New York, NY 10029-6574, USA.

Reviews on Recent Clinical Trials

|May 14, 2008

Summary

Alefacept is a new immunobiologic treatment for plaque psoriasis. This review covers its efficacy, safety, and potential uses for other conditions based on recent case reports.

Area of Science:

Immunology
Dermatology

Background:

Plaque psoriasis is a chronic autoimmune skin condition.
Alefacept is a novel immunobiologic agent approved for psoriasis treatment.

Purpose of the Study:

To review the efficacy and safety of alefacept.
To explore potential new applications of alefacept based on case reports.

Main Methods:

Literature review of alefacept's clinical data.
Analysis of recent case reports on alefacept usage.

Main Results:

Alefacept demonstrates a specific efficacy and safety profile in plaque psoriasis treatment.
Emerging case reports suggest potential utility in other conditions.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Related Experiment Videos

Last Updated: Jul 5, 2026

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Published on: November 8, 2024

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Conclusions:

Alefacept is an important therapeutic option for plaque psoriasis.
Further research is warranted to explore alefacept's broader therapeutic potential.